BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25277672)

  • 1. The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions.
    Kroep S; Lansdorp-Vogelaar I; van der Steen A; Inadomi JM; van Ballegooijen M
    Med Decis Making; 2015 Aug; 35(6):726-33. PubMed ID: 25277672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
    Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
    Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
    Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus.
    Wolf WA; Pasricha S; Cotton C; Li N; Triadafilopoulos G; Muthusamy VR; Chmielewski GW; Corbett FS; Camara DS; Lightdale CJ; Wolfsen H; Chang KJ; Overholt BF; Pruitt RE; Ertan A; Komanduri S; Infantolino A; Rothstein RI; Shaheen NJ
    Gastroenterology; 2015 Dec; 149(7):1752-1761.e1. PubMed ID: 26327132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma.
    Whiteman DC; Appleyard M; Bahin FF; Bobryshev YV; Bourke MJ; Brown I; Chung A; Clouston A; Dickins E; Emery J; Eslick GD; Gordon LG; Grimpen F; Hebbard G; Holliday L; Hourigan LF; Kendall BJ; Lee EY; Levert-Mignon A; Lord RV; Lord SJ; Maule D; Moss A; Norton I; Olver I; Pavey D; Raftopoulos S; Rajendra S; Schoeman M; Singh R; Sitas F; Smithers BM; Taylor AC; Thomas ML; Thomson I; To H; von Dincklage J; Vuletich C; Watson DI; Yusoff IF
    J Gastroenterol Hepatol; 2015 May; 30(5):804-20. PubMed ID: 25612140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas.
    Corley DA; Mehtani K; Quesenberry C; Zhao W; de Boer J; Weiss NS
    Gastroenterology; 2013 Aug; 145(2):312-9.e1. PubMed ID: 23673354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the Diagnosis and Treatment of Barrett's Esophagus and Early Esophageal Cancer; Summary of the Kelly and Carlos Pellegrini SSAT/SAGES Luncheon Symposium.
    Gould JC; Wendling MR; Oeschlager BK; Mittal SK; Komanduri S; Perry KA; Cleary S; Galandiuk S; Scott DJ; Fisichella PM; Shaheen NJ; Haisley KR; Hunter JG
    J Gastrointest Surg; 2017 Aug; 21(8):1342-1349. PubMed ID: 28243981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
    Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
    Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Screening for adenocarcinoma in Barrett's esophagus: yes or no, when and how?].
    Sostres C; Lacarta P; Lanas A
    Gastroenterol Hepatol; 2013 Oct; 36(8):520-6. PubMed ID: 23453559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study.
    Wani S; Holmberg D; Santoni G; Kauppila JH; Farkkila M; von Euler-Chelpin M; Shaheen NJ; Lagergren J
    Gastroenterology; 2023 Oct; 165(4):909-919.e13. PubMed ID: 37279832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling.
    Kroep S; Lansdorp-Vogelaar I; Rubenstein JH; de Koning HJ; Meester R; Inadomi JM; van Ballegooijen M
    Gastroenterology; 2015 Sep; 149(3):577-85.e4; quiz e14-5. PubMed ID: 25935635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis.
    Codipilly DC; Chandar AK; Singh S; Wani S; Shaheen NJ; Inadomi JM; Chak A; Iyer PG
    Gastroenterology; 2018 Jun; 154(8):2068-2086.e5. PubMed ID: 29458154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of cancer risk in Barrett's esophagus.
    Tan A; Macrae F
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1485-92. PubMed ID: 21592226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.